Achieve Life Sciences Inc. has released a corporate presentation highlighting Cytisinicline as a potential new treatment for nicotine dependence, marking the first advancement in nearly 20 years. The company targets a substantial market of up to 50 million Americans who use tobacco, aiming to address the significant public health issue of nicotine dependence. The presentation outlines the anticipated FDA approval timeline, with a smoking cessation NDA filed and a launch expected in the second half of 2026. Additionally, the company is preparing for Phase 3 trials for an e-cigarette cessation indication, which holds an FDA Breakthrough Therapy designation and Priority Review. Achieve Life Sciences plans a focused launch strategy utilizing innovative, data-driven solutions to promote adoption and future growth. You can access the full presentation through the link below.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。